Generalized Myasthenia Gravis Clinical Trials in Washington D.C., District of Columbia

5 studies are recruiting for generalized myasthenia gravis in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

   The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of o…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The George Washington University Medical Faculty Associates Foggy Bottom South Pavilion, Washington D.C., District of Columbia

   Locations

   153 in total

   Run by

   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

   See if you can join NCT06463587 on ClinicalTrials.gov

2. Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

   The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

   Stage

   Phase 3

   Ages

   18 to 80

   Site

   Site Number - 1024, Washington D.C., District of Columbia

   Locations

   88 in total

   Run by

   Immunovant Sciences GmbH

   See if you can join NCT07039916 on ClinicalTrials.gov

3. A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

   A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Medstar Washington Hospital Center, Washington D.C., District of Columbia

   Locations

   130 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06744920 on ClinicalTrials.gov

4. PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

   The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Research Site, Washington D.C., District of Columbia

   Locations

   13 in total

   Run by

   Alexion Pharmaceuticals, Inc.

   See if you can join NCT06607627 on ClinicalTrials.gov

5. Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

   Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).

   Stage

   Not phased

   Ages

   18 and older

   Site

   Clinical Trial Site, Washington D.C., District of Columbia

   Locations

   51 in total

   Run by

   Alexion Pharmaceuticals, Inc.

   See if you can join NCT04202341 on ClinicalTrials.gov